SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 16, 2005--Hana Biosciences (AMEX: HBX), a biopharmaceutical company focused on advancing cancer care, today announced management promotions and changes which will accelerate development of the company's pipeline and enable rapid commercialization of its first product, which is targeted for 2007 launch.
"We are leveraging the strength of our management team to accelerate the pace, intensity and focus of our operations," said Mark Ahn, Ph.D., president and CEO. "2005 has been a year of significant progress for Hana. We're excited about reaching our growth objectives for 2006 and beyond."
